Manufacturing Perspectives: Lessons for Biomanufacturing from Small-Molecule Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Manufacturing Perspectives: Lessons for Biomanufacturing from Small-Molecule Manufacturing
A perspective from Pfizer on the lessons from small-molecule manufacturing that can be applied to biomanufacturing.

Pharmaceutical Technology
Volume 35, pp. s6-s8

As biopharmaceutical product-development intensifies, what knowledge can be applied from small-molecule manufacturing? Lou Schmukler, senior vice-president of the Specialty/ Biotechnology Operating Unit at Pfizer, shares his perspective on process understanding and control, operational excellence principles, and cultural and organizational transformation.

Illustration: Melissa McEvoy; Images Don Farrall/Photodisc.
The biotechnology industry has come a long way in a relatively short time. Over a period of just three decades, the industry has gone from consisting of only start-up companies to businesses that in aggregate will exceed $125 billion in global revenues this year. There are more than 30 biotechnology products with annual sales of $1 billion or greater. Biotechnology is the fastest-growing sector of the bio/pharmaceutical industry with growth highest in vaccines and emerging markets. Biotechnology companies' pipelines are replete with more than 5600 candidates that are currently in clinical trials and are designed to treat a plethora of different diseases. Forecasts project that by 2014, seven of the world's top 10 pharmaceutical products will come from biotechnology companies, according to data from Evaluate Pharma. This impressive performance reflects tremendous technological advancement and innovation across the biotechnology value chain. Biotechnology has brought extraordinary and novel therapies to treat cancers, diabetes, pneumococcal disease, rheumatoid arthritis, hemophilia, bone growth, and anemia, for example.

This period of strong drug development ushered in significant progress and improvement in bioprocessing. With the development of recombinant DNA technology in the 1970s and the creation of monoclonal antibodies, organizations began tackling the challenge of effectively and efficiently producing new biotechnology products. A transformation has long been underway, which has moved biomanufacturing from art to science and has challenged the notion that once characterized biomanufacturing as "the process is the product." In the mid-1980s, achieving yields in quantities of milligrams per liter in monoclonal antibodies was an accomplishment. Today, by incorporating bioprocessing-intensification strategies of the past 15 years, biomanufacturing organizations now routinely can produce yields in quantities of multigrams per liter with an increased emphasis on economics, quality, process robustness, and reliability.

The progress in biomanufacturing has been truly remarkable, and we can expect continued progress in upstream and downstream process optimization, new analytical technologies, application of single-use and modular technologies, multiproduct facilities, higher expression-system productivity, and new delivery systems. Growth in emerging markets and the resulting need to address access and affordability issues will challenge current biomanufacturing-supply strategies. In addition, the emergent biosimilar market will require special capabilities from today's biomanufacturing organizations. In short, the continued dynamics of the business and regulatory environment will further drive change.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here